Synapse - Works

Results (13087)

A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma

Meeting Abstract

Patel, S.; McKean, M.; Piperno-Neumann, S.; Shoushtari, A. N.; Hernandez-Aya, L.; Orloff, M.; Khan, S.; Montazeri, K.; Kapiteijn, E.; Buchbinder, E.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

Meeting Abstract

Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma

Meeting Abstract

Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors

Meeting Abstract

Garcia, V. M.; Calvo, E.; Asch, A.; Butler, M.; Zugazagoitia, J.; Charlson, J.; Cervantes, A.; Van Tine, B.; Aggen, D.; Clarke, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

Meeting Abstract

O'Cearbhaill, R. E.; Moore, K. N.; Yeku, O.; Liu, J. F.; Bouberhan, S.; Hamilton, E. P.; Hou, J. Y.; Van Nieuwenhuysen, E.; Papadimitriou, K.; Yoo, S. Y.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study

Meeting Abstract

Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S. E.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
American Journal of Hematology (2023)

Fulltext@MSK | Save

Ecoritamab SSC with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma, including patients with POD24: Updated results from EPCORE NHL-2

Meeting Abstract

Merryman, R. W.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
American Journal of Hematology (2023)

Fulltext@MSK | Save

Subcutaneous epcoritamab with R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated results from EPCORE NHL-2

Meeting Abstract

Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J. D.; Kim, M. L.; Snauwaert, S.; Cordoba, R.; Oki, T.; Bykhovski, I.; more...
American Journal of Hematology (2023)

Fulltext@MSK | Save

Pooled analysis of MagnetisMM studies: Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to B-cell maturation antigen (BCMA)-directed therapies

Meeting Abstract

Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maise, C.; Arnulf, A.; Larson, S. M.; Asya, V. Y. N.; Leleu, X.; Karlin, L.; more...
American Journal of Hematology (2023)

Fulltext@MSK | Save

A subgroup analysis from MagnetisMM-3: the efficacy and safety of elranatamab by age and frailty in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Raje, N.; Leleu, X.; Lesokhin, A. M.; Mohty , M.; Nooka, A.; Leip, E.; Conte, U.; Vlqueira, A.; Manier, S.
American Journal of Hematology (2023)

Fulltext@MSK | Save